Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors

被引：0
|
作者：
Dumbrava, Ecaterina Elena
Cecchini, Michael
Zugazagoitia, Jon
Lopez, Juanita Suzanne
Jager, Dirk
Oliva, Marc
Ochsenreither, Sebastian
Gambardella, Valentina
Chung, Ki Y.
Longo, Federico
Razak, Albiruni Ryan Abdul
Wermke, Martin
Evans, T. R. Jeffry
Cook, Natalie
Chenard-Poirier, Maxime
Pencheva, Radost
Schaer, David
Wagener, Thomas
Wagner, Andrea
Papadopoulos, Kyriakos P.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Yale Univ, Sch Med, New Haven, CT USA
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Royal Marsden NHS Trust, Sutton, Surrey, England
[5] NCT Heidelberg, Heidelberg, Germany
[6] Lhosp & Inst Invest Biomed Bellvitge IDIBELL, ICO, Barcelona, Spain
[7] Charite Univ Med Berlin, Berlin, Germany
[8] INCLIVA Biomed Res Inst, Valencia, Spain
[9] Prisma Hlth Canc Inst, Greenville, SC USA
[10] Hosp Univ Ramo y Cajal, Madrid, Spain
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
[12] Tech Univ Dresden, Fac Med, NCT UCC Early Clin Trial Unit, Dresden, Germany
[13] Univ Glasgow, Glasgow, Lanark, Scotland
[14] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[15] Univ Manchester, Manchester, Lancs, England
[16] Univ Laval, CHU Quebec, Quebec City, PQ, Canada
[17] Bayer PLC, Reading, Berks, England
[18] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[19] Bayer AG, Berlin, Germany
[20] START San Antonio, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2502
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results.
    Capelan, Marta
    Kumar, Prasana
    Tolcher, Anthony W.
    Zivi, Andrea
    Desai, Madhuri
    Papadopoulos, Kyriakos P.
    Senaldi, Giorgio
    Patnaik, Amita
    Banerji, Udai
    Rasco, Drew D.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [32] First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors
    Guo, Ye
    Wang, Zishu
    Zhou, Huan
    Pan, Hongming
    Han, Weidong
    Deng, Yanhong
    Li, Qun
    Xue, Junli
    Ge, Xiaoxiao
    Wang, Shuang
    Wang, Jing
    Zhang, Yue
    Zhao, Congqiao
    Zhu, Huaqiang
    Wang, Yu
    Shen, Haige
    Liu, Dong
    Li, Jin
    BMC CANCER, 2024, 24 (01)
  • [33] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Azaro, A.
    Rodon, J.
    Herranz, M.
    Nuciforo, P.
    Prudkin, L.
    Lopez-Busto, N.
    Balandraud, S.
    Cattan, V.
    Jacquet-Bescond, A.
    Marfai, L.
    Pauly, J.
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54
  • [34] First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors
    Piha-Paul, Sarina A.
    Xu, Binghe
    Dumbrava, Ecaterina E.
    Fu, Siqing
    Karp, Daniel D.
    Meric-Bernstam, Funda
    Hong, David S.
    Rodon, Jordi A.
    Tsimberidou, Apostolia M.
    Raghav, Kanwal
    Ajani, Jaffer A.
    Conley, Anthony P.
    Mott, Frank
    Fan, Ying
    Fan, Jean
    Peng, Peng
    Wang, Hui
    Ni, Shumao
    Sun, Caixia
    Qiang, Xiaoyan
    Levin, Wendy J.
    Ngo, Brenda
    Ru, Qinhua Cindy
    Wu, Frank
    Javle, Milind M.
    ONCOLOGIST, 2024, 29 (04): : e514 - e525
  • [35] A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
    Lee S. Rosen
    Patricia LoRusso
    Wen Wee Ma
    Jonathan W. Goldman
    Amy Weise
    A. Dimitrios Colevas
    Alex Adjei
    Salim Yazji
    Angela Shen
    Stuart Johnston
    Hsin-Ju Hsieh
    Iris T. Chan
    Branimir I. Sikic
    Investigational New Drugs, 2016, 34 : 604 - 613
  • [36] A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors
    Brunetto, A. T.
    Ang, J. E.
    Lal, R.
    Olmos, D.
    Frentzas, S.
    Mais, A.
    Hauns, B.
    Mollenhauer, M.
    Lahu, G.
    de Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] A first-in-human phase I dose escalation study of BET inhibitor GSK2820151 in patients with advanced or recurrent solid tumors cancers
    Gadgeel, Shirish
    Keedy, Vicki
    Taylor, Simon
    Amin, Khalid
    Homer, Thierry
    Wu, Yuehui
    Prinjha, Rab
    Dhar, Arindam
    Kremer, Brandon
    CANCER RESEARCH, 2017, 77
  • [38] A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
    Varga, A.
    Soria, J. C.
    Hollebecque, A.
    LoRusso, P.
    Vaishampayan, U.
    Okrah, K.
    Huang, S. M. A.
    Murray, E.
    Sanabria-Bohorquez, S.
    Tagen, M.
    Dokainish, H.
    Mueller, L.
    Burris, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
  • [39] A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Varga, Andrea
    Soria, Jean-Charles
    Hollebecque, Antoine
    LoRusso, Patricia
    Bendell, Johanna
    Huang, Shih-Min A.
    Wagle, Marie-Claire
    Okrah, Kwame
    Liu, Lichuan
    Murray, Elaine
    Sanabria-Bohorquez, Sandra M.
    Tagen, Michael
    Dokainish, Hatem
    Mueller, Lars
    Burris, Howard
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1229 - 1236
  • [40] A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
    Rosen, Lee S.
    LoRusso, Patricia
    Ma, Wen Wee
    Goldman, Jonathan W.
    Weise, Amy
    Colevas, A. Dimitrios
    Adjei, Alex
    Yazji, Salim
    Shen, Angela
    Johnston, Stuart
    Hsieh, Hsin-Ju
    Chan, Iris T.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (05) : 604 - 613
12345